Medicine and Dentistry
Cohort Analysis
87%
Rheumatoid Arthritis
86%
Population
31%
Psoriatic Arthritis
28%
Janus Kinase Inhibitor
28%
Cancer Risk
28%
TNF Inhibitor
28%
Malignant Neoplasm
24%
Disease-Modifying Antirheumatic Drug
19%
Biological Product
19%
COVID-19
19%
Infection
19%
Mortality
19%
Hazard Ratio
15%
Rheumatology
13%
Severe Acute Respiratory Syndrome Coronavirus 2
12%
Rituximab
12%
Proportional Hazards Model
11%
Tocilizumab
10%
Rheumatic Disease
10%
Childbirth
10%
Subacute Cutaneous Lupus Erythematosus
9%
Interstitial Lung Disease
9%
Hematologic Malignancy
9%
Premature Mortality
9%
Respiratory Failure
9%
Omega-3 Fatty Acid
9%
Diet and Cancer
9%
Spondylarthritis
9%
Psoriasis
9%
Immunomodulating Agent
9%
Virus Infection
9%
Venous Thromboembolism
9%
Odds Ratio
9%
Abatacept
9%
Systemic Lupus Erythematosus
9%
Chronic Pain
9%
Case-Control Study
9%
Glucocorticoid
9%
Methotrexate
9%
Cardiovascular Disease
9%
Disease Modifying Antirheumatic Drug
7%
Interleukin 6
6%
Standardized Incidence Ratio
5%
Cumulative Incidence
5%
Biological Therapy
5%
Diseases
5%
Keyphrases
Rheumatoid Arthritis
57%
National Cohort Study
40%
Denmark
28%
Polyautoimmunity
19%
JAK Inhibitors
19%
TNF Inhibitors
19%
Systemic Lupus Erythematosus
19%
Psoriatic Arthritis
19%
COVID-19 Hospitalization
19%
Janus Kinase Inhibitor
19%
Cancer Risk
19%
COVID-19 Incidence
15%
Incidence Rate
14%
Hazard Ratio
12%
COVID-19
11%
RA Patients
10%
Population-based
10%
Danish Registers
10%
Register Study
10%
IL-6 Inhibitors
9%
Venous Thromboembolic Events
9%
N-3 Polyunsaturated Fatty Acids
9%
Rheumatoid Arthritis Protocol
9%
Biological Disease-modifying Antirheumatic Drugs (bDMARDs)
9%
Solid Cancer
9%
Hematological Malignancies
9%
Cutaneous Lupus Erythematosus
9%
Danish Population
9%
Matched Cohort Study
9%
Fracture Risk
9%
Cardiac Events
9%
Viral Infection
9%
New User
9%
Sarilumab
9%
Osteoporotic Fractures
9%
Health Registers
9%
SARS-CoV-2 Infection
9%
Temporal Trends
9%
Anti-cyclic Citrullinated Peptide Antibody (anti-CCP)
9%
Inflammatory Rheumatic Diseases
9%
Nave
8%
Systemic Lupus Erythematosus Patient
7%
Tumour Necrosis Factor Inhibitor (TNFi)
7%
Biologic DMARDs
7%
Rheumatology
7%
Hospitalization
6%
Interleukin-6 Inhibitors
6%
Nationwide Registers
5%
Severe COVID-19
5%
Standardized Incidence Ratio
5%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
100%
Rheumatoid Arthritis
57%
Tumor Necrosis Factor Inhibitor
35%
Janus Kinase Inhibitor
28%
Infection
25%
Malignant Neoplasm
25%
Psoriatic Arthritis
20%
Skin Lupus Erythematosus
19%
Systemic Lupus Erythematosus
19%
Rheumatic Disease
19%
SARS Coronavirus
14%
Prevalence
12%
Disease Modifying Antirheumatic Drug
11%
Biological Product
11%
Vaccination Policy
10%
Hematologic Malignancy
9%
Fragility Fracture
9%
Venous Thromboembolism
9%
Virus Infection
9%
Sarilumab
9%
Abatacept
9%
Autoimmune Disease
8%
Lupus Erythematosus
7%
Comorbidity
6%
Interleukin 6
6%
Standardized Incidence Ratio
5%